A patient on levothyroxine 100 µg has thyroid‑stimulating hormone (TSH) 13.5 mIU/L, free thyroxine (free T4) 1.02 ng/dL, and free triiodothyronine (free T3) 2.1 pg/mL; what adjustment to the levothyroxine dose is recommended?

Levothyroxine Dose Adjustment Recommendation

Increase the levothyroxine dose by 12.5 to 25 µg (to 112.5-125 µg daily), recheck TSH in 6-8 weeks, and continue titrating until TSH normalizes to the reference range.

Rationale for Dose Increase

Your patient has overt hypothyroidism with TSH 13.5 mIU/L (markedly elevated) despite being on levothyroxine 100 µg. The current dose is clearly insufficient. The 2012 AACE/ATA guidelines explicitly state that when subclinical or overt hypothyroidism is noted in levothyroxine-treated patients, the dosage should be adjusted to bring serum TSH into the reference range 12.

Specific Dosing Algorithm

Immediate Action:

• Increment size: Increase by 12.5-25 µg increments 22
• New dose: 112.5 µg or 125 µg daily
• Timing: The FDA label confirms titration by 12.5-25 µg increments every 4-6 weeks until euthyroid 3

Follow-up Monitoring:

• Recheck TSH in 6-8 weeks after dose adjustment 223
• TSH levels may take 4-6 weeks to plateau after dose changes, particularly with smaller increments 2
• Continue adjusting in 12.5-25 µg increments until TSH reaches the reference range

Critical Considerations Before Adjusting

Rule Out Non-Compliance First:

Patients on high doses (>200 µg/day) with persistently elevated TSH are most commonly non-compliant rather than having absorption issues 22. At 100 µg with TSH 13.5, consider:

• Medication adherence: Is the patient taking it consistently?
• Timing: Is it taken 30-60 minutes before breakfast on an empty stomach? 22
• Interfering substances: Check for concurrent use of calcium, iron, proton pump inhibitors, or other medications that impair absorption 22

Assess for Malabsorption:

If compliance is confirmed, consider:

• Gastrointestinal disorders (celiac disease, inflammatory bowel disease)
• Medications interfering with absorption (see Table 10 in guidelines: calcium, iron, PPIs, bile acid sequestrants) 22
• Recent weight gain (increases requirements)

Target TSH Range

Goal: TSH within the normal reference range (typically 0.5-5.0 mIU/L, though some prefer 0.4-2.5 mIU/L) 12

The guidelines note that when patients continue to have symptoms despite TSH in the upper half of the reference range, it's reasonable to target the lower portion of the reference range 1. However, the primary goal is simply normalization first.

Special Populations Requiring Caution

The standard 12.5-25 µg increment applies to most patients, but slower titration is warranted if your patient:

• Is >50-60 years old: Start lower, titrate every 6-8 weeks 23
• Has cardiac disease or atrial fibrillation risk: Slower titration to avoid cardiac exacerbation 23
• Has coronary artery disease: Monitor for anginal symptoms 2

For these patients, consider the smaller 12.5 µg increment and extend monitoring intervals to 6-8 weeks.

Common Pitfalls to Avoid

1. Adjusting too quickly: Wait the full 6-8 weeks before making another change 22
2. Ignoring compliance: Address adherence before assuming malabsorption 22
3. Not checking for drug interactions: Many medications interfere with levothyroxine absorption 22
4. Overlooking timing of administration: Absorption is significantly reduced if taken with food or within 30 minutes of breakfast 22

Why Not a Larger Increase?

While TSH >10 mIU/L indicates more severe hypothyroidism 1, the guidelines consistently recommend incremental adjustments of 12.5-25 µg rather than large jumps 223. This approach:

• Prevents overshooting into hyperthyroidism
• Allows physiologic equilibration
• Reduces cardiovascular risk, especially in older patients

The FDA label explicitly states that dosages >200 µg/day are seldom required, and inadequate response to >300 µg/day suggests poor compliance, malabsorption, or drug interactions 3.